PLAU and familial pancreatic carcinoma: In addition, uPA inhibitors have also demonstrated very encouraging outcomes in clinical trials for the treatment of different types of solid tumours (136, 137), including using Upamostat (WX-671, Mesupron) in advanced pancreatic cancer patients (138, 139).